RT @JAMAOphth: Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy https://t.co/VPh7VkYOS2 #mos…
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy https://t.co/VPh7VkYOS2 #mostcited
RT @JAMAOphth: Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy https://t.co/VPh7VkYOS2 #mos…
RT @JAMAOphth: Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy https://t.co/VPh7VkYOS2 #mos…
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy https://t.co/VPh7VkYOS2 #mostcited
#PanFotocoagulaciónRetiniana vs #Ranibizumab intravítreo para #RetinopatíaDiabéticaProliferativa (JAMA Oph) El grupo d #Ranibizumab tuvo tasas más bajas d desarrollar #EdemaMacularDiabético con discapacidad visual y menos pérdida d #CampoVisual Acceso ab
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy... - via Researcher https://t.co/CMo6QnFgYN https://t.co/y7irWkBc4t
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative #DiabeticRetinopathy @JAMAOphth | #ECM https://t.co/27xgE3vjR9
RT @MentorMeMd: Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative #Diabetic #Retinopathy: A…
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative #Diabetic #Retinopathy: A Randomized Clinical Trial | #JAMA #Ophthalmology | JAMA Network https://t.co/jfzBPupWkn #EyeMed #Meded #Research #Ophthalmology #Oph
RT @JAMAOphth: https://t.co/vIdERcbrqw Protocol S 5-year outcomes for PDR, either PRP or #ranibizumab yield good mean VA; severe #visionlos…
RT @JAMAOphth: https://t.co/vIdERcbrqw Protocol S 5-year outcomes for PDR, either PRP or #ranibizumab yield good mean VA; severe #visionlos…
RT @SurgeonRetina: 5 Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab in Proliferative Diabetic Retinopathy: ranib…
|Artículo|Se han publicado en JAMA Ophthalmology los resultados a cinco años del estudio que compara la fotocoagulación panretiniana versus ranibizumab intravítreo para la retinopatía diabética proliferativa. Más detalles: https://t.co/PSJ8cWFeRU #SERV18 #
5-year prospective trial of PRP vs anti-VEGF for proliferative diabetic retinopathy shows high loss to follow-up but good visual acuity in most study eyes of both groups that completed trial. Better macular edema prevention with anti-VEGF. https://t.co/6UZ
RT @SurgeonRetina: 5 Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab in Proliferative Diabetic Retinopathy: ranib…
RT @SurgeonRetina: 5 Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab in Proliferative Diabetic Retinopathy: ranib…
RT @SurgeonRetina: 5 Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab in Proliferative Diabetic Retinopathy: ranib…
RT @SurgeonRetina: 5 Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab in Proliferative Diabetic Retinopathy: ranib…
RT @SurgeonRetina: 5 Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab in Proliferative Diabetic Retinopathy: ranib…
RT @ghanchif: 5 year follow up data on PDR @eye_kelly @SimonPHarding @The_Eye_Doctor @praveenjpatel https://t.co/ItYbUkYlUc
RT @SurgeonRetina: 5 Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab in Proliferative Diabetic Retinopathy: ranib…
RT @JAMAOphth: https://t.co/vIdERcbrqw Protocol S 5-year outcomes for PDR, either PRP or #ranibizumab yield good mean VA; severe #visionlos…
5 Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab in Proliferative Diabetic Retinopathy: ranibizumab group w lower rates of diabetic macular edema & less visual field loss, otherwise comparable. Congrats @UMKelloggEye Dr. Gard
5 year follow up data on PDR @eye_kelly @SimonPHarding @The_Eye_Doctor @praveenjpatel https://t.co/ItYbUkYlUc
https://t.co/vIdERcbrqw Protocol S 5-year outcomes for PDR, either PRP or #ranibizumab yield good mean VA; severe #visionloss rare. Learn more from @AdamGlassman1 https://t.co/TpOQKZW42m #ASRS2018 https://t.co/1PUkYWIGSh